Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trastuzumab biosimilar - Biocad

Next Previous
Drug Profile

Trastuzumab biosimilar - Biocad

Alternative Names: BCD-022; HERtiCAD

Latest Information Update: 28 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocad
  • Developer Biocad; SPH-BIOCAD
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Gastric cancer; HER2 positive breast cancer

Most Recent Events

  • 28 Sep 2025 No recent reports of development identified for preclinical development in HER2-positive-breast-cancer in China (IV, Infusion)
  • 07 Oct 2016 Efficacy and safety data from a phase III trial in Breast cancer presented at the 41st European Society for Medical Oncology Congress (ESMO - 2016)
  • 01 Oct 2016 Biocad completes a phase III trial in Her2 positive Breast cancer (Combination therapy, First-line therapy, Metastatic disease) in Russia, India, Ukraine and Belarus (IV) (NCT01764022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top